An innovative approach to using IGF signalling pathways to target cancer is to use them to direct therapies to the tumour, for example, they can be conjugated to nanoparticles to enhance targeting and penetration of the tumour (Zhou et al., 2015)
Discontinuation rates within the first year are consistently reported between approximately 45 and 75% (Sikirica et al., 2017
Beyond pancreatic -cells, GLP-1R is also found on various other cell types, such as neuronal cells, cardiovascular cells, gastrointestinal smooth muscle cells, and immune cells [10,11,12,13,14,15,16,17] (Fig
A recent analysis of over 50 million insured lives found that GLP-1 users experienced 44% fewer hospitalizations for major cardiovascular events, and healthcare spending rose at just half the rate of similar non-users by year two
A pilot clinical trial on L-carnitine supplementation in combination with motivation training: effects on weight management in healthy volunteers